

Care for Complex Patients – Clinical Approaches to Quality Improvement at the Intersection of Substance Use Disorder, Mental Illness, and Chronic Pain

Benjamin Springgate MD, MPH
Stefan Kertesz MD, MSc
Chinazo Cunningham MD, MS
Karran Phillips MD, MSc







Stefan Kertesz, MD, MSc

Professor of Medicine,
University of Alabama at
Birmingham Heersink School of
Medicine



Benjamin Springgate MD, MPH, FACP

Professor of Medicine and Public Health LSU Health - New Orleans



Chinazo Cunningham, MD, MS

Commissioner of the New York State Office of Addiction Services and Supports (OASAS)



Karran Phillips, MD, MSc

Deputy Director, Center for Substance Abuse and Treatment

Substance Abuse and Mental Health Services Administration (SAMHSA)





Care for Complex Patients: Clinical Approaches to Quality Improvement at the Intersection of Substance Use Disorder, Mental Illness, and Chronic Pain

Stefan Kertesz, MD, MSc

Professor of Medicine, University of Alabama at Birmingham Heersink School of Medicine





Disclosures

Stefan Kertesz, MD, MSc

Certified: Addiction Medicine, Internal Medicine

Professor, University of Alabama at Birmingham Heersink School of Medicine

Opinions are my own and not those of my employers



COMMUNITIES

FAMILIES





INDIVIDUALS





READY







My purpose

- I will introduce a case example to teach a decisional framework for long-term pain care when the patient's condition and history are challenging
 - There are many dimensions to the decision
 - The case introduces overlap between pain care and opioid use disorder care
 - The OUD implication should help prepare for the next few speakers
- But my unique objective is to illustrate
 - Some current policies that appear to be "about opioids" often wind up at odds with good, individualized care
 - Good care has to be "about this patient, the one in front of me"



Jimmy comes to Medical Walk-In, a resident clinic

- A 59 year old "Jimmy": requests oxycodone for back & shoulder pain
- Recently lost home in East Alabama, moved to live with brother
- 3 emergency department and 1 primary care visit in last 18 days
- Some information from the chart
 - PTSD, opioid use disorder in the past,
 - Long term pain, diabetes
 - MRI: severe stenoses at multiple lumbar and cervical levels
 - Neurosurgery consult was requested
- Teaching doctor says "we ordinarly don't start opioids on a walk-in patient"
- In fact, this medical center reduced opioids by 75% in last 8 years



More information from Jimmy's visit and chart

- 18 days ago, in the ED: hydrocodone (#12) + ketorolac injection + methocarbamol and an antibiotics
- 10 days ago, in the ED: oxycodone (#12) + ketorolac injection
- 4 days ago, in the primary care department: diclofenac gel, lidocaine patch, acetaminophen
- The team also managed diabetes, initiated workup for weight loss of 95 pounds
- 3 days ago in the ED: out of oxycodone. The doctor spoke to neurosurgery.
 Ordered: 3 days of cyclobenzaprine, a steroid "dose pack", and an interventional anesthesia consult
- Within 24 hours, the consult was canceled by the anesthesiologist
- Jimmy sits in wheelchair, cachectic (115lbs), flinching in pain. He alludes to suicide tangentially but denies intent
- Jimmy expresses distrust and hostility


Jimmy's story in the chart

- Other info
 - PTSD and "Opioid Use Disorder" are mentioned in chart
 - Jimmy says "yes, as a younger man, I used heroin and cocaine"
 - In 12 years of health records, only marijuana mentioned
 - Chronic neck/back pain started in 2006
 - 2 years of opioids, stopped in 2016 when he tested positive for marijuana
 - Appears to have continued in diabetes care therafter
 - Weight fell from 200 lbs in 2018, to 112 lbs in late 2023




Here's a Simple Line I Find Unhelpful







Two Simple lines I find unhelpful



A Series of Steps to Evaluate Pain Care Decisions Mental Social Support Or traumas (e.g., PTSD) Biological

Non-opioid medication

Prescription opioid

Nonpharmacological modalities

Other choices



Patient

with pain

& tissue

injuries

A Series of Steps to Evaluate Pain Care Decisions 2 Non-opioid medication Social Mental support SUDs, health or current & diagnosis traumas remitted (e.g., Prescription PTSD) Meds with opioid dependence Biological effects & tissue injuries Non-**Patient** pharmacological with pain Disability modalities Health Other choices system trauma distrust

Resilient and Ready Together

A Series of Steps to Evaluate Pain Care Decisions 3

Social Mental support SUDs, health or current & dx's (e.g traumas remitted PTSD) Meds with dependence Biological effects & tissue injuries **Patient** with pain Disability **Timeline** available Health system trauma Life distrust context What was Competing already medical offered concerns

Non-opioid medication

Prescription opioid

Nonpharmacological modalities

Other choices



Definitions for two domains

■ Patient Context: Everything that is expressed outside of a patient's skin that is relevant to planning their care. This does overlap with content of the other considerations. However, it may include living environment, or financial situation, or cultural beliefs

 What was already offered: This refers to treatments already attempted, and whether they worked well, poorly, or not at all Past biological injury + new severe illness

PTSD is present

Trauma seems probable

Social support is 1 relative

Probable remitted opioid use disorder

Possible cannabis use disorder

Jimmy's decision concerns

Many short-term treatments were offered and none helped

There is an urgent competing medical concern requiring workup


Life context is traumatic

Disability is obvious

Distrust is understandable

5 visits with no progress

Someone cut off his pain meds too




Jimmy follow-up

- The Veterans Affairs opioid risk stratification tool actually suggested lower risk than we projected: 3% risk of OD/suicide "event" in 1 year
- I kneel in front of his wheelchair & look up. I affirm he is in a devastating situation. I say any decision about opioids is sensitive & poses risks for him and is "sensitive" legally.

I present 4 options:

- (a) Hospitalize today for weight loss and pain
- (b) Start duloxetine for pain and possible depression
- (c) Diclofenac gel
- (d) Low-dose off-label buprenorphine (2 mg three times a day) with follow-up
- Jimmy takes (b) and (d)
- We did informed consent
- Our decision may still look bad to my employer's internal guideline or to payors



Three commonly measured aspects of opioid care that may be right for Jimmy and look wrong in current policy standards

	Quality Measure or Policy	Source	What it Might Mean for Jimmy
Opioid duration	Risk of continued opioid use (>15 days in 30 day period)	National Committee for Quality Assurance	Jimmy's care may require a prescription that will be refused or held against the prescriber
Opioid dose	Initial Opioid Prescribing at High Dosage	Pharmacy Quality Alliance and CMS	Jimmy may require over 50 morphine milligram equivalents. Probably not, but the situation and history set up for that
Choice of buprenorphine	Buprenorphine should be allowed for pain only after failure of traditional opioids	Common among many health plans	He may be refused buprenorphine formulations by the payor



A Public Health Approach to the Overdose Epidemic

Chinazo Cunningham, MD, MS
Commissioner, Office of Addiction Services and Supports (OASAS)



Public Health in New York State

Physical Health



Department of Health

Hospitals
Emergency rooms
FQHCs/Clinics
Long term care facilities
Medicaid

Behavioral Health



Office of Addiction
Services and Supports

Office of Mental Health

- >750 staff
- >\$1 billion annual budget
- >1700 addiction programs
- >730,000 individuals

Certify, regulate, support all addiction services in NYS






Epidemiology of Overdose Deaths





Overdose Deaths in the U.S. (2013 – 2022)




All Drug Overdose Deaths
===: All Opioids
===: Fentanyl
Cocaine
Heroin
===: Natural and semisynthetic opioids

—— Psychostimulants excl. cocaine



Overdose Deaths in NYS Continue to Increase

Drug overdose deaths by substance: New York, 1999 – 2022*







The Intersection of Substance Use and Mental Health






Mental Health and Substance Use Disorders among New Yorkers with Medicaid (2022)

(N = 180,398)

Characteristics	SUD Population

ANY Co-Occurring Mental Health Disorder	122,497	68%
Anxiety	63,260	52%
Major Depressive Disorder	40,824	33%
Bipolar	23,391	19%
Adjustment	21,998	18%
Psychotic Disorder	19,054	16%
Impulse control and behavioral disorder	18,583	15%

SUD Non-Crisis Treatment Population with MH Diagnosis Receiving MH Treatment (2020)





Healthcare for Individuals, Families, and Communities

Integrating Treatment Services






Initiatives to Address Mental Health and Substance Use Disorders

- Certified Community Behavioral Health Clinics
 - Tripling state clinics from 13 to 39
- Funding for 22 Crisis Stabilization Centers
- Integrated Outpatient Model
- Cross-agency training and funding opportunities across NYS health agencies
- Collaborative Prevention
- Workforce Investments & Initiatives



Integrated Prevention Services

Working with NYS Office of Mental Health to integrate substance use disorder, mental health & suicide prevention across systems.



Community-Based Coalitions: Substance use disorder & suicide prevention on community-wide level





State-Run Addiction Treatment Centers Mental Health Assessment and Treatment

- All patients admitted to all 12 addiction treatment centers are screened for suicide risk and mental health disorders.
- Patients with mental health symptoms or disorders receive a complete psychiatric evaluation within 72 hours.
- One addiction treatment center focused on people with severe mental illness—with expansion into a second center.




Opioid Settlement Funds

✓ ALL funds (\$192.8M) made available in 2023

✓ 2023 Opioid Settlement Fund Advisory Board Annual Report

Online spending tracker

- By priority area
- By initiative
- By county
- By fiscal year (2023 & 2024)





Guiding Principles

- Data-driven, evidence-based approach
- Harm Reduction
- Equity





Meaningful Data

Make better use of data

• Make data more available and accessible

Initiatives:

- Addiction Data Bulletins
- Dashboards
- NIH-funded research



KATHY HOCHUL Governor CHINAZO CUNNINGHAM, MD Commissioner

Addiction Data Bulletin

New York State Substance Use Disorder Treatment Service System

URPOSE OF THIS BULLETIN

This bulletin provides a summary of New Yorkers who received treatment for substance use disorder (SUD) in programs and services overseen by the New York State Office of Addiction Services and Supports (OASAS) in 2022.

KEY TAKEAWAYS

- Recent data indicate that 2.8 million New Yorkers aged 12 years and older had a SUD in the past year.
- Provisional data indicate that 6,358 New York State residents died of a drug overdose in 2022 and 2,003 died from alcohol-related causes.
- Of individuals admitted to SUD treatment in 2022, the plurality (39.5%) were admitted into outpatient treatment.
- Of all individuals receiving SUD treatment in 2022, 40.7% received treatment at an opioid treatment program (OTP).
- Of individuals admitted to SUD treatment in 2022, 72.0% were male and 27.9% were female.
- Of individuals admitted to SUD treatment in 2022, half (52.4%) were aged 25-44 years; the next largest age group was those aged 55 years and older (20.6%), followed by individuals aged 45-54 years (19.3%) and those aged 24 years and younger (7.7%).

- Most SUD treatment admissions in 2022 were among those living in the Upstate New York region (47.2%), followed by those living New York City (38.7%) and Long Island (14.1%).
- 48.6% of individuals admitted to SUD treatment in 2022 identified as White, followed by Black (24.5%) and Hispanic (21.8%).
- Of primary substances of use reported at admission in 2022, alcohol was the most common (55%) followed by heroin (23.9%). Compared to other races and ethnicities, Black individuals had the highest percent of admissions for alcohol use (52.3%). Hispanic and White individuals had the highest percent of admissions for heroin use (29.5% and 26.1%, respectively compared to Black individuals.
- Among all SUD treatment admissions between 2017 and 2022, primary substance used at admission increased by 21.8% for alcohol and decreased by 24.4% for heroin.

SUBSTANCE USE DISORDERS IN NEW YORK STATE

As described by the Substance Abuse and Mental Health Services Administration (SAMHSA), 'SUbs' occur when the recurrent use of alcohal and/or drugs causes clinically significant inpairment, Including health problems, disability, and failure to meet major responsibilities at work, school, or home." Estimates from the 2021 National Survey on Drug Use and Health (NSDUH) indicate that 2.8 million New Yorkers aged 12 years and older had a SUD in the past year. SUbs are associated with numerous potential adverse impacts to the health and well-being of an individual as well as their family and community.

One of the most serious SUD-related outcomes is death due to drug overdose. According to provisional data from the CDC* in 2022, 6,358 New York State residents died of a drug overdose. Opioids were a primary or contributing factor in 84.3% of drug overdose deaths, 92.3% of opioid-related drug overdose deaths included synthetic opioids such as fentanyi; synthetic opioids were present in 77.9% of drug overdose deaths overall." Provisional CDC data indicated that 2,003 New York residents ided from alcohol-related causes in 2022."



Incorporating Harm Reduction Across New York State


The OASAS Division of Harm Reduction

Overdose Prevention

- ✓ Naloxone
- ✓ Fentanyl & xylazine test strips
- ✓ Drug checking machines
- ✓ Drug deactivation bags
- ✓ Medication lock bags

Outreach & Engagement

- ✓ Clinic- and street-level outreach
- √ Homeless shelter initiative
- √ Care coordination
- ✓ Transportation



Incorporating an Equity Lens Across New York State

Office of Justice, Equity, Diversity & Inclusion (JEDI)

Internal activities

- ✓ JEDI Advisory Council
- ✓ Organizational equity assessment
- ✓ Addressing appropriate language
- Equity procurement criteria

External activities

- ✓ State-wide interagency workgroup
- ✓ Lived Experience Advisory Panel (LEAP)
- ✓ Trainings, tools, and guidance for staff providers
- ✓ Equity Leadership Institute
- ✓ Language Access



OASAS. Every Step of the Way.











SAMHSA: Integrated Behavioral Healthcare

Karran Phillips, MD, MSc

Deputy Director, Center for Substance Abuse Treatment, SAMHSA



Treatment among People with Co-Occurring Substance Use Disorder and Mental Illness (NSDUH, 2022)


Among the 21.5 million adults aged 18 or older with co-occurring AMI and an SUD in the past year


- 59.1% (or 12.7 million people) received either substance use treatment or mental health treatment in the past year
- Most of those received only mental health treatment (64.1%)

Among the 7.4 million adults aged 18 or older with co-occurring SMI and an SUD in the past year

- 71.2% (or 5.3 million people) received either substance use treatment or mental health treatment in the past year
- Most of those received only mental health treatment (63.1%)

SAMHSA Priorities





https://bit.ly/410lMbe

Integrating Behavioral and Physical Health Care: SAMHSA Goals

Integration of behavioral and physical health care by using systematic, evidence-based, costeffective approaches to improve person-centered comprehensive care in all settings with the aim of the creation of health and wellbeing – not just the absence of disease.

1. To promote whole-person care and improve health outcomes, SAMHSA will advance bi-directional integration of health care services across systems for people with behavioral health conditions.

2. To promote whole-person care and improve health outcomes, SAMHSA will advance policies and programs to address social determinants of health.

Integrating Behavioral and Physical Health Care: SAMHSA Efforts

Grant Programs	Training/Technical Assistance
Screening, Brief Intervention, and Referral to Treatment (SBIRT) SAMHSA	National Center of Excellence for Integrated Health Solutions SAMHSA
Minority AIDS Initiative: Substance Use Disorder Treatment for Racial/Ethnic Minority Populations at High Risk for HIV/AIDS SAMHSA	Expanding Access to and Use of Behavioral Health Services for People Experiencing Homelessness SAMHSA Publications and Digital Products
Adult Reentry Program SAMHSA	SAMHSA Harm Reduction Framework SAMHSA
Certified Community Behavioral Health Clinics (CCBHCs) SAMHSA	Your Guide to Integrating HCV Services into Opioid Treatment Programs Addiction Technology Transfer Center (ATTC) Network (attcnetwork.org)

Additional programs: Grants for the Benefit of Homeless Individuals Treatment for Individuals Experiencing Homelessness, Projects for Assistance in Transitioning from Homelessness, Adult Treatment Drug Court, Assertive Community Treatment Grants, Substance Use Prevention Treatment Recovery Services Block Grants



Minority AIDS Initiative

\$21.9 million for the Minority AIDS Initiative:
Substances Use Disorder Treatment for
Racial/Ethnic Minority Populations at High
Risk for HIV/AIDS.

This program increases engagement in care for racial and ethnic medically underserved individuals with substance use disorders (SUDs) and/or co-occurring SUDs and mental health conditions (COD) who are at risk for or living with HIV. Award recipients will take a syndemic approach to SUD, HIV and viral hepatitis. HCV testing and referral to treatment is a required activity.

\$1.9 million for the Minority HIV/AIDS Fund: Integrated Behavioral Health and HIV Care for Unsheltered Populations Pilot Project.

This pilot program provides comprehensive healthcare for racial and ethnic medically underserved people experiencing unsheltered homelessness through the delivery of portable clinical care delivered outside that is focused on the integration of behavioral health and HIV treatment and prevention services. HCV testing and referral to treatment is a required activity.

Certified Community Behavioral Health Clinics










- Bring a comprehensive range of services together, incorporating evidence-based practices and other supports based on a community needs assessment
- Provide for improved access to mental health and substance use disorder (MH/SUD) services, including increased capacity to respond to MH+SUD crises
- Serve individuals across the lifespan with mental health and/or substance use disorders
- Meet CCBHC Certification Criteria



Map of CCBHCs Across the United States (as of March 2023)



Federal CCBHC Medicaid Demonstration (And SAMHSA Expansion Grants) State contains at least one local SAMHSA expansion grantee

- CMS-approved payment method for CCBHCs via a SPA or 1115 waiver separate from Demonstration
- Chosen to receive one-year planning grant needed to join Medicaid Demonstration staring in March 2023

- There are now more than 500 CCBHCs across 46 States, the District of Columbia, and Puerto Rico
- CCBHCs may be a part of the Section 223 Medicaid Demonstration, Independent State programs, or participating in SAMHSA's expansion grants.
- 15 states have been selected to participate in planning grants to prepare to join the Section 223 Medicaid Demonstration:
- Alabama, Delaware, Georgia, Iowa, Kansas, Maine, Mississippi, Montana, North Carolina, New Hampshire, New Mexico, Ohio, Rhode Island, Vermont, West Virginia.
- After year-long planning grant period, states will apply to be one of 10 states to be able to join the Medicaid Demonstration starting July 1, 2024



SAMHSA's Harm Reduction Framework

SAMHSA's aim is to integrate harm reduction activities and approaches across its organizational Centers and initiatives, and to do so in a manner that draws on evidence-based practice and principles — while also maintaining sustained dialogue with harm reductionists and people who use drugs (PWUD).



Is led by
PWUD and
with lived
experience of
drug use

Embraces the inherent value of people

Commits to
deep
community
engagement
and
community
building

Promotes equity, rights, and reparative social justice

Offers most accessible and noncoercive support

Focuses on any positive change, as defined by the person

Resilient and Ready Together

Harm reduction strategies reduce HIV and hepatitis C infection among people who inject drugs, reduce overdose risk, enhance health and safety, and increase by five-fold the likelihood of a person who injects drugs to initiate substance use disorder treatment.^{1, 2, 3}

SAMHSA Publications and Digital Products

The SAMHSA Evidence-Based Practice Resource Center (EBRC) contains resources for a range of audiences related to best practices for the treatment of OUD/SUDs and integration of SUD treatment into a variety of settings



Thank you

SAMHSA's mission is to lead public health and service delivery efforts that promote mental health, prevent substance misuse, and provide treatment and supports to foster recovery while ensuring equitable access and better outcomes.



FindSupport.gov

FindTreatment.gov

988Lifeline.org

www.SAMHSA.gov

1-877-SAMHSA7 (1-877-726-4727)

1-800-487-4889 (TDD)





Commentary, Discussion, and Questions



COMMUNITIES

FAMILIES





INDIVIDUALS

RESILIENT



READY





